CA2201040A1 - Solid pharmaceutical preparation, comprising 5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide - Google Patents
Solid pharmaceutical preparation, comprising 5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilideInfo
- Publication number
- CA2201040A1 CA2201040A1 CA002201040A CA2201040A CA2201040A1 CA 2201040 A1 CA2201040 A1 CA 2201040A1 CA 002201040 A CA002201040 A CA 002201040A CA 2201040 A CA2201040 A CA 2201040A CA 2201040 A1 CA2201040 A1 CA 2201040A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical preparation
- anilide
- methylisoxazole
- carboxylic acid
- solid pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
A solid pharmaceutical preparation comprising 5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide is prepared in an essentially anhydrous manner.
Description
s. - 2 2 0 ~ ~ 4 0 HOECHSTAKTIENGESELLSCHAFT HOE 96/F 073 Dr. Th/we Description Solid pharmaceutical preparation, comprising 5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide European Patent Application, publication number 0 013 376 A2, discloses that 5-methylisoxazole4-carboxylic acid (4-trifluoromethyl)anilide (compound 1) has antirheumatic, antiinflammatory, antipyretic and analgesic activity and can be employed against multiple sclerosis.
Pharmaceuticals comprising the active compound 5-methylisoxazole-15 4-carboxylic acid (4-trifluoromethyl)anilide are administered orally in doses of 5mgto 150mg.
European Patent Application, publication number 0 217 206 A2, discloses that N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide (compound 20 2) has immunomodulating properties and is suitable as a pharmaceutical against chronic graft-versus-host diseases and against autoimmune disorders, in particular systemic lupus erythematosus. Pharmaceuticals comprising the active compound N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide are administered in doses from 50 mg to 200 mg.
It has now been found that the production of solid pharmaceutical preparations, comprising compound 1, for example in tablet form, leads during storage to the formation of 6% to 9% of compound 2, the percentage data relating to compound 1. Compound 2 is formed here from 30 compound 1 during storage. Pharmaceutical preparations containing 6 to 9% contamination by other active compounds are not adequate for modern therapy, as they make difficult an accurately dosed, constant, controlled administration of the compound 1.
~ . 220~040 The invention aims, by modification of the production process, at making available a pharmaceutical preparation comprising compound 1 in which substantially less compound 2 is formed during storage.
The object is achieved by the production of the pharmaceutical preparation comprising compound 1 being carried out in an essentially anhydrous manner.
The invention therefore relates to a solid pharmaceutical preparation comprising 5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide and a pharmaceutically tolerable excipient, which comprises compressing 5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide and the pharmaceutically tolerable excipient in an essentially anhydrous manner to give a solid pharmaceutical preparation.
The preparation of 5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl)-anilide is carried out according to EP 0 013 376. The pharmaceutically tolerable excipient employed can be, for example, lactose, corn starch, polyvinylpyrrolidone, highly disperse silica, cellulose, polyethylene glycol, polyglycol or magnesium stearate.
After 6 months' storage at 40~C and 75% humidity in air, the solid pharmaceutical preparations according to the invention have an N-(4-tri-fluoromethylphenyl)-2-cyano-3-hydroxycrotonamide content of 1.0 to 4.5%, as a rule of 1.5% to 4%, in particular of 1.5% to 3.5%; in each case based on the content of the compound 1, which is set at 100%.
The expression "solid pharmaceutical preparation" means preparations such as tablets, capsules, powders, suppositories or granules. The expression "in an essentially anhydrous manner" means that dry active compound and dry auxiliaries are employed and no additional water is employed in the production of the pharmaceutical preparation.
~ - 2 2 ~ ~ a 4 0 The content of 5-methylisoxazole-4-carboxylic acid (4-trifluoro-methyl)anilide in a solid pharmaceutical preparation is 2 mg to 250 mg, preferably 5 mg to 150 mg, in particular 10 mg to 50 mg7 particularly preferably 10 mg to 20 mg.
The production of the pharmaceutical preparation according to the invention is carried out, for example, by direct tableting, dry granulation and tableting or by production of granules by melt solidification and subsequent tableting. In direct tableting, the binding between the powder 10 particles is effected by the use of high mechanical pressures (Pharmazeutische Technologie [Pharmaceutical Technology], Bauer, Fromming, Fuhrer, 3rd Edition, Georg Thieme Verlag Stuttgart, New York (1991 ) pages 292 - 307). The melt solidification granules are produced either by melting and shock-freezing, by pouring out and comminuting or 15 by spray solidification in spray towers (Pharmazeutische Technologie, page 295). In dry granulation, the bindings between the powder particles to be granulated are effected by the use of high mechanical pressures. This can be achieved both using tablet presses, relatively large tablets or briquettes resulting as intermediates, and using compacting rolls, which 20 yield scales. The scales or briquettes obtained are then comminuted using counter-rotating toothed rolls and/or put through sieves (Pharmazeutische Technologie, page 295). For example, the compound 1 and one or more of the pharmaceutically tolerable excipients are mixed without addition of water. The dry auxiliaries such as binders, flow agents, glidants and 25 lubricants are then added and the mixture is compressed to give solid tablets.
The compound 1 can further be mixed with lactose, microcrystalline cellulose and Macrogol 6000 (polyethylene glycol) in a high-speed mixer, 30 the material being heated by friction and forming granules. The cooled granules are passed through a screen of 1.2 mm mesh width and dusted with magnesium stearate. The granules are then compressed to give ~ 2 2 0 ~ 0 4 o ~ ~ 4 tablets.
The solid pharmaceutical preparations according to the invention differ from tablets which have been produced by moist granulation by a differing 5 release behavior of the active compound. The solid pharmaceutical preparation according to the invention shows a release of 70% to 85% of the active compound after 15 minutes, preferably of 76% to 80% and, after 30 minutes, of 85% to 95%, preferably of 88% to 92%.
10 Tablets which have been prepared by the moist granulation method show a release of 87% to 92% of the active compound after 15 minutes, and, after 30 minutes, a release of 93% to 98%.
~ O ~ ~ 4 0 Example 1 Direct tableting The following are needed for one tablet:
10.0 mg of 5-methylisoxazole-4-carboxylic acid (4-trifluoro-methyl)anilide (I) 78.0 mg of lactose (Il); (Meggle Milchindustrie GmbH &
Co. KG, Wasserburg) 50.0 mg of corn starch(lll); (Cerestar Benelux B. V., Sas van Gent, Netherlands) 100.5 mg of highly disperse silica (IV); (Degussa AG, Rheinfelden) 7.5 mg of crosslinked poly(1-vinyl-2-pyrrolidone) (V);
(BASF, Ludwigshafen) and 0.5 mg of magnesium stearate (Vl); (Otto Balocher GmbH, Munich) The components I to lll are mixed for 5 minutes in a paddle mixer. The components IV to Vl are then added and mixed for a further 60 seconds (ready-to-press mixture). The ready-to-press mixture is compressed to give 20 tablets having a final weight of 146.5 mg each.
After 6 months' storage at 40~C with an air humidity of 75%, the tablets have a content of the compound 2 of 1.5%, based on the content of the compound 1.
Example 2 Spray granulation The following are needed for 1 tablet:
10.0 mg of 5-methylisoxazole-4-carboxylic acid (4-trifluoro-methyl)anilide (I) 78.0 mg of lactose (Il) 50.0 mg of corn starch (Ill) ~ t û 4 ~
3.5 mg of poly(1-vinyl-2-pyrrolidone) K25 (IV); (BASF, Ludwigshafen) 0.5 mg of highly disperse silica (V) 7.5 mg of crosslinked poly(1-vinyl-2-pyrrolidone) (Vl) 0.5 mg of magnesium stearate (Vll) The components I to lll are mixed for 5 minutes in a tumble mixer. Poly(1-vinyl-2-pyrrolidone) is dissolved in water (5 to 7.5 percent strength solution) and sprayed onto the mixed components I to lll in a spray tower at an 10 incoming air temperature of approximately 60~C and an outgoing air temperature of approximately 21~C. The product is then dried. The spray granules obtained are transferred to a mixer and mixed for 60 seconds with the components V to Vll. The ready-to-press mixture is processed as in Example 1 to give tablets having a final weight of 150 mg.
After 6 months' storage at 40~C at an air humidity of 75%, the tablets have a content of the compound 2 of 8.3%, based on the compound 1.
Example 3 20 Release of compound 1 from tablets 1 tablet each according to Examples 1 and 2 is added to 100 ml of water each. After 15 minutes and after 30 minutes, the amount of compound 1 in the supernatant is determined. Table 1 shows the results.
220~ Q~
~ , _ ' 7 Table 1:
Tablet according to Release after Release after 15 minutes 30 minutes Example 2 92 % + 3.1 % 98 % + 1.1 %
Example 1 77 % + 1.0 % 88 % +1.1 %
Pharmaceuticals comprising the active compound 5-methylisoxazole-15 4-carboxylic acid (4-trifluoromethyl)anilide are administered orally in doses of 5mgto 150mg.
European Patent Application, publication number 0 217 206 A2, discloses that N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide (compound 20 2) has immunomodulating properties and is suitable as a pharmaceutical against chronic graft-versus-host diseases and against autoimmune disorders, in particular systemic lupus erythematosus. Pharmaceuticals comprising the active compound N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide are administered in doses from 50 mg to 200 mg.
It has now been found that the production of solid pharmaceutical preparations, comprising compound 1, for example in tablet form, leads during storage to the formation of 6% to 9% of compound 2, the percentage data relating to compound 1. Compound 2 is formed here from 30 compound 1 during storage. Pharmaceutical preparations containing 6 to 9% contamination by other active compounds are not adequate for modern therapy, as they make difficult an accurately dosed, constant, controlled administration of the compound 1.
~ . 220~040 The invention aims, by modification of the production process, at making available a pharmaceutical preparation comprising compound 1 in which substantially less compound 2 is formed during storage.
The object is achieved by the production of the pharmaceutical preparation comprising compound 1 being carried out in an essentially anhydrous manner.
The invention therefore relates to a solid pharmaceutical preparation comprising 5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide and a pharmaceutically tolerable excipient, which comprises compressing 5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide and the pharmaceutically tolerable excipient in an essentially anhydrous manner to give a solid pharmaceutical preparation.
The preparation of 5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl)-anilide is carried out according to EP 0 013 376. The pharmaceutically tolerable excipient employed can be, for example, lactose, corn starch, polyvinylpyrrolidone, highly disperse silica, cellulose, polyethylene glycol, polyglycol or magnesium stearate.
After 6 months' storage at 40~C and 75% humidity in air, the solid pharmaceutical preparations according to the invention have an N-(4-tri-fluoromethylphenyl)-2-cyano-3-hydroxycrotonamide content of 1.0 to 4.5%, as a rule of 1.5% to 4%, in particular of 1.5% to 3.5%; in each case based on the content of the compound 1, which is set at 100%.
The expression "solid pharmaceutical preparation" means preparations such as tablets, capsules, powders, suppositories or granules. The expression "in an essentially anhydrous manner" means that dry active compound and dry auxiliaries are employed and no additional water is employed in the production of the pharmaceutical preparation.
~ - 2 2 ~ ~ a 4 0 The content of 5-methylisoxazole-4-carboxylic acid (4-trifluoro-methyl)anilide in a solid pharmaceutical preparation is 2 mg to 250 mg, preferably 5 mg to 150 mg, in particular 10 mg to 50 mg7 particularly preferably 10 mg to 20 mg.
The production of the pharmaceutical preparation according to the invention is carried out, for example, by direct tableting, dry granulation and tableting or by production of granules by melt solidification and subsequent tableting. In direct tableting, the binding between the powder 10 particles is effected by the use of high mechanical pressures (Pharmazeutische Technologie [Pharmaceutical Technology], Bauer, Fromming, Fuhrer, 3rd Edition, Georg Thieme Verlag Stuttgart, New York (1991 ) pages 292 - 307). The melt solidification granules are produced either by melting and shock-freezing, by pouring out and comminuting or 15 by spray solidification in spray towers (Pharmazeutische Technologie, page 295). In dry granulation, the bindings between the powder particles to be granulated are effected by the use of high mechanical pressures. This can be achieved both using tablet presses, relatively large tablets or briquettes resulting as intermediates, and using compacting rolls, which 20 yield scales. The scales or briquettes obtained are then comminuted using counter-rotating toothed rolls and/or put through sieves (Pharmazeutische Technologie, page 295). For example, the compound 1 and one or more of the pharmaceutically tolerable excipients are mixed without addition of water. The dry auxiliaries such as binders, flow agents, glidants and 25 lubricants are then added and the mixture is compressed to give solid tablets.
The compound 1 can further be mixed with lactose, microcrystalline cellulose and Macrogol 6000 (polyethylene glycol) in a high-speed mixer, 30 the material being heated by friction and forming granules. The cooled granules are passed through a screen of 1.2 mm mesh width and dusted with magnesium stearate. The granules are then compressed to give ~ 2 2 0 ~ 0 4 o ~ ~ 4 tablets.
The solid pharmaceutical preparations according to the invention differ from tablets which have been produced by moist granulation by a differing 5 release behavior of the active compound. The solid pharmaceutical preparation according to the invention shows a release of 70% to 85% of the active compound after 15 minutes, preferably of 76% to 80% and, after 30 minutes, of 85% to 95%, preferably of 88% to 92%.
10 Tablets which have been prepared by the moist granulation method show a release of 87% to 92% of the active compound after 15 minutes, and, after 30 minutes, a release of 93% to 98%.
~ O ~ ~ 4 0 Example 1 Direct tableting The following are needed for one tablet:
10.0 mg of 5-methylisoxazole-4-carboxylic acid (4-trifluoro-methyl)anilide (I) 78.0 mg of lactose (Il); (Meggle Milchindustrie GmbH &
Co. KG, Wasserburg) 50.0 mg of corn starch(lll); (Cerestar Benelux B. V., Sas van Gent, Netherlands) 100.5 mg of highly disperse silica (IV); (Degussa AG, Rheinfelden) 7.5 mg of crosslinked poly(1-vinyl-2-pyrrolidone) (V);
(BASF, Ludwigshafen) and 0.5 mg of magnesium stearate (Vl); (Otto Balocher GmbH, Munich) The components I to lll are mixed for 5 minutes in a paddle mixer. The components IV to Vl are then added and mixed for a further 60 seconds (ready-to-press mixture). The ready-to-press mixture is compressed to give 20 tablets having a final weight of 146.5 mg each.
After 6 months' storage at 40~C with an air humidity of 75%, the tablets have a content of the compound 2 of 1.5%, based on the content of the compound 1.
Example 2 Spray granulation The following are needed for 1 tablet:
10.0 mg of 5-methylisoxazole-4-carboxylic acid (4-trifluoro-methyl)anilide (I) 78.0 mg of lactose (Il) 50.0 mg of corn starch (Ill) ~ t û 4 ~
3.5 mg of poly(1-vinyl-2-pyrrolidone) K25 (IV); (BASF, Ludwigshafen) 0.5 mg of highly disperse silica (V) 7.5 mg of crosslinked poly(1-vinyl-2-pyrrolidone) (Vl) 0.5 mg of magnesium stearate (Vll) The components I to lll are mixed for 5 minutes in a tumble mixer. Poly(1-vinyl-2-pyrrolidone) is dissolved in water (5 to 7.5 percent strength solution) and sprayed onto the mixed components I to lll in a spray tower at an 10 incoming air temperature of approximately 60~C and an outgoing air temperature of approximately 21~C. The product is then dried. The spray granules obtained are transferred to a mixer and mixed for 60 seconds with the components V to Vll. The ready-to-press mixture is processed as in Example 1 to give tablets having a final weight of 150 mg.
After 6 months' storage at 40~C at an air humidity of 75%, the tablets have a content of the compound 2 of 8.3%, based on the compound 1.
Example 3 20 Release of compound 1 from tablets 1 tablet each according to Examples 1 and 2 is added to 100 ml of water each. After 15 minutes and after 30 minutes, the amount of compound 1 in the supernatant is determined. Table 1 shows the results.
220~ Q~
~ , _ ' 7 Table 1:
Tablet according to Release after Release after 15 minutes 30 minutes Example 2 92 % + 3.1 % 98 % + 1.1 %
Example 1 77 % + 1.0 % 88 % +1.1 %
Claims (7)
1. A process for the production of a solid pharmaceutical preparation, comprising 5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl)-anilide, which comprises producing the pharmaceutical preparation in an essentially anhydrous manner.
2. The process as claimed in claim 1, wherein direct tableting or dry granulation with subsequent tableting is carried out.
3. The process as claimed in claim 1, wherein granulation by melt solidification is carried out.
4. The process as claimed in one or more of claims 1 to 3, wherein the auxiliaries employed are lactose, corn starch, highly disperse silica, crosslinked poly(1-vinyl-2-pyrrolidone), microcrystalline cellulose, polyethylene glycol, polyglycol or magnesium stearate.
5. A solid pharmaceutical preparation, obtainable by direct tableting of 5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide and a pharmaceutically tolerable excipient.
6. A solid pharmaceutical preparation, obtainable by dry granulation or granulation by melt solidification and tableting of 5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide and a pharmaceutically tolerable excipient.
7. A solid pharmaceutical preparation, as claimed in claim 5 or 6, wherein the pharmaceutically tolerable excipient employed is lactose, corn starch, highly disperse silica, crosslinked poly (1-vinyl-2-pyrrolidone), microcrystalline cellulose, polyethylene glycol, polyglycol or magnesium stearate.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19612131.0 | 1996-03-27 | ||
| DE19612131A DE19612131A1 (en) | 1996-03-27 | 1996-03-27 | Solid drug preparation containing 5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl) anilide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2201040A1 true CA2201040A1 (en) | 1997-09-27 |
Family
ID=7789602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002201040A Abandoned CA2201040A1 (en) | 1996-03-27 | 1997-03-26 | Solid pharmaceutical preparation, comprising 5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0797989A1 (en) |
| JP (1) | JPH107547A (en) |
| AU (1) | AU1651397A (en) |
| CA (1) | CA2201040A1 (en) |
| DE (1) | DE19612131A1 (en) |
| NZ (1) | NZ314479A (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ23088U1 (en) | 2004-03-25 | 2011-12-19 | Astellas Pharma Inc. | Composition of solifenacin or salt thereof for use in solid formulation |
| US7815939B2 (en) | 2005-07-20 | 2010-10-19 | Astellas Pharma Inc. | Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms |
| DE102006017896A1 (en) * | 2006-04-13 | 2007-10-25 | Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg | Leflunomide-containing pharmaceutical compositions |
| KR100868295B1 (en) | 2007-02-15 | 2008-11-11 | 풍림무약주식회사 | Solid dispersion containing leflunomide and preparation method thereof |
| CN108014081A (en) * | 2017-12-28 | 2018-05-11 | 福建汇天生物药业有限公司 | A kind of leflunomide tablet of stability and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3534440A1 (en) * | 1985-09-27 | 1987-04-02 | Hoechst Ag | DRUGS AGAINST CHRONIC GRAFT VERSUS HOST DISEASES AND AUTO AUTO DISEASES, IN PARTICULAR SYSTEMIC LUPUS ERYTHEMATODES |
-
1996
- 1996-03-27 DE DE19612131A patent/DE19612131A1/en not_active Ceased
-
1997
- 1997-03-14 EP EP97104344A patent/EP0797989A1/en not_active Withdrawn
- 1997-03-25 AU AU16513/97A patent/AU1651397A/en not_active Abandoned
- 1997-03-25 NZ NZ314479A patent/NZ314479A/en unknown
- 1997-03-26 JP JP9072937A patent/JPH107547A/en active Pending
- 1997-03-26 CA CA002201040A patent/CA2201040A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JPH107547A (en) | 1998-01-13 |
| NZ314479A (en) | 1998-08-26 |
| AU1651397A (en) | 1997-10-02 |
| EP0797989A1 (en) | 1997-10-01 |
| MX9702290A (en) | 1997-09-30 |
| DE19612131A1 (en) | 1998-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6607750B2 (en) | Directly compressible acetaminophen compositions | |
| US5006345A (en) | Direct tableting auxiliary | |
| CA1338553C (en) | Pharmaceutical granulate containing cellulose product | |
| EP0377658B1 (en) | A free-flowing granular composition containing ibuprofen and a method for its preparation | |
| US4661521A (en) | Direct tableting acetaminophen compositions | |
| KR890001526A (en) | Oral sustained release acetaminophen formulations and preparation method thereof | |
| AU1211992A (en) | Low dose dry pharmaceutical preparations | |
| JPH1067651A (en) | Auxiliary agent for direct tableting, tablet comprising the same auxiliary agent and production of tablet | |
| EP0782449A1 (en) | Process of making dosage units by wet granulation | |
| IE76142B1 (en) | Solvent-free pharmaceutical formulation to be administered orally having delayed release of active ingredient and process for its preparation | |
| CA2371231A1 (en) | Pharmaceutical composition in unit form containing acetylsalicylic acid and clopidogrel hydrogenosulphate | |
| JP4709379B2 (en) | Pharmaceutical formulation containing levothyroxine sodium | |
| CA2435714C (en) | Fenofibrate tablets | |
| RU2159618C2 (en) | Compacted desogostrel tablets, preparation thereof by dry granulation technique | |
| EP0181650B1 (en) | Compression-coated dispersible tablets | |
| US5137732A (en) | Riboflavin granules containing no inactive ingredient | |
| CA2201040A1 (en) | Solid pharmaceutical preparation, comprising 5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide | |
| KR20010072269A (en) | Pharmaceutical compositions comprising ibuprofen and domperidone | |
| UA27954C2 (en) | Biologically active substance of a pharmaceutical composition for treatment of hyperglycemias and pharmaceutical composition having antihyperglicemical activity | |
| FI103179B (en) | Process for making molded, pressed, delayed release dosage units | |
| JPH08310969A (en) | Solid pharmaceutical composition and its preparation | |
| JPS6346726B2 (en) | ||
| KR20010033233A (en) | Method and device for producing pharmaceutical formulations containing an extract | |
| JP2007332074A (en) | Tablet quickly disintegrable in oral cavity and method for producing the same | |
| US5560927A (en) | Co-processing method for making a free-flowing compressible powder and tablet therefrom |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |